Irritable bowel syndrome is a gastrointestinal tract disorder characterized by abdominal pain and altered bowel habits. It hampers the natural movement of intestinal muscle linings to move food along the digestive tract. Depending on the symptoms, the syndrome is distinguished as mild and severe irritable bowel syndrome. These symptoms include cramping, abdominal pain, bloating and gas, mucus in the stool, constipation, and diarrhea. Exact cause of occurrence of irritable bowel syndrome is unknown though, it is associated with increased awareness of bodily functions, and abnormal gastrointestinal tract movements. Diagnosis of irritable bowel syndrome is done by tests such as blood tests, stool tests, endoscopic procedures, and external imaging procedures. Patients suffering from irritable bowel syndrome may experience complications namely, deep ulcerations, infections, malnutrition, and bowel obstructions.
The global irritable bowel syndrome treatment market is estimated to be valued at US$ 1,444.7 million in 2022 and is expected to exhibit a CAGR of 13.2% during the forecast period (2022-2030).
Figure 1. Global Irritable Bowel Syndrome Treatment Market Share (%), by Medical Condition, 2022
Growing prevalence of irritable bowel syndrome as well as impact of dietary factors on gut health are expected to drive growth of the global irritable bowel syndrome treatment market.
The increasing prevalence of irritable bowel syndrome (IBS) is expected to drive the market growth over the forecast period. For instance, according to an article published by Cureus, an open access general medical journal, in January 2021, a cross-section study was conducted in the internal medicine unit of a tertiary care hospital in multiple cities of Pakistan from June 2019 to August 2019, to find out the prevalence of IBS in healthy population and determine the characteristics of symptoms. According to the results, the prevalence of IBS in general population was 33.2%.
|Base Year:||2021||Market Size in 2022:||US$ 1,444.7 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2020 to 2027|
|Forecast Period 2022 to 2030 CAGR:||13.2%||2030 Value Projection:||US$ 3,902.9 Mn|
Abbott, Synergy Pharma, Mallinckrodt, Bausch Health Companies Inc., Ardelyx, Astellas Pharma Inc., Novartis AG, GSK plc., Ironwood Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.
|Restraints & Challenges:||
Figure 2.Global Irritable Bowel Syndrome Treatment Market Share (%), by Region, 2022
Rise in research & development activities for the development of irritable bowel syndrome drugs are expected to drive the market growth during the forecast period.
Increasing research and development activities by the key players in the market for the development of irritable bowel syndrome drugs are expected to drive the market growth over the forecast period. For instance, in June 9, 2022, Ferring B.V., a biopharmaceutical company, announced that it had entered into a strategic collaboration with I-MAB Biopharma Co., Ltd., an innovation-driven global biopharma company, to further develop olamkicept, a selective interleukin-6 (IL-6) trans-signaling inhibitor for inflammatory bowel disease (IBD) and related inflammatory conditions.
Global Irritable Bowel Syndrome Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.
However, the COVID-19 pandemic had a positive impact on the global irritable bowel syndrome (IBS) treatment market, owing to the increased stress, abdominal pain, diarrhea in patients infected with COVID-19 infection. For instance, according to an article published by the National Center for Biotechnology Information, providing access to biomedical and genomic information, in February 2022, the COVID-19 pandemic is reported to increase psychological distress and
Global Irritable Bowel Syndrome Treatment Market: Key Developments
In April 2022, Ardelyx, a biopharmaceutical company, announced the launch of IBSRELA, the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is the first U.S. Food and Drug Administration approved product for Ardelyx.
In March 2022, Indegene, a technology-led healthcare solutions provider, and metaMe Health, a Prescription Digital Therapeutics (PDT) company and developer of Regulora, partnered to bring Regulora to market for the treatment of abdominal pain due to Irritable Bowel Syndrome (IBS).
Global Irritable Bowel Syndrome Treatment Market: Restraint
The major factors that hinder growth of the global irritable bowel syndrome treatment market include side effects of the drugs. For instance, Eluxadoline, a mixed mu-opioid receptor agonist, used to treat irritable bowel syndrome with diarrhea can cause pancreatitis, an inflammation of the pancreas which can be serious and more common in certain individuals.
Major players operating in the global irritable bowel syndrome treatment market include Abbott, Synergy Pharma, Mallinckrodt, Bausch Health Companies Inc., Ardelyx, Astellas Pharma Inc., Novartis AG, GSK plc., Ironwood Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.
The treatment of irritable bowel syndrome majorly revolves around relieving the patient from the symptoms associated with the condition, as the causes behind occurrence of irritable bowel syndrome are yet unknown. Patients suffering from irritable bowel syndrome show symptoms such as abdominal pain, diarrhea, and constipation. Long-term and recurring presence of these symptoms signals the possibility of irritable bowel syndrome. The treatment depends on severity of these symptoms, which are distinguished as mild, moderate, and severe. Mild symptoms do not significantly affect the quality of life. However, severe symptoms are more frequent and intense and need to be addressed. The disease is often linked with dietary, lifestyle factors, and stress, which can be controlled by managing stress levels, diet, and exercise. Severe symptoms need to be treated through medication prescribed by physicians. Two major therapy options are available for the treatment of IBS, namely, medical or drug therapy and nutritional therapy. Medical therapy includes drugs for relieving the symptoms and nutritional therapy by using fibers and probiotics or prebiotics depending on the situation.
The rise in number of gastrointestinal disorders are leading to increasing prevalence of irritable bowel syndrome (IBS), for which various companies such as Ironwood Pharmaceuticals, Inc., conduct mass workshops for educating the people to incorporate healthy food habits as a major precaution towards prevention of IBS. Moreover, major growth drivers for the irritable bowel syndrome treatment market are expected to launch various pipeline drugs for the treatment of irritable bowel syndrome during the forecast period and increase in levels of stress associated with changing lifestyle as people suffering from IBS have a colon with sensitivity towards certain foods and stress. For instance, according to the data provided by International Foundation for Gastrointestinal Disorders, a non-profit, educational and research organization, it’s estimated that 5-10% of the population has IBS worldwide. According to the same source, stress does not cause IBS. However, because of the connection between the brain and the gut, stress can worsen or trigger the symptoms.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.